Objectives: The aim of this study was to model the in vivo transporter-mediated uptake and efflux of the hepatobiliary contrast agent gadoxetate in the liver. The efficacy of the proposed technique was assessed for its ability to provide quantitative insights into drug-drug interactions (DDIs), using rifampicin as inhibitor. Materials and Methods: Three groups of C57 mice were scanned twice with a dynamic gadoxetate-enhanced magnetic resonance imaging protocol, using a 3-dimensional spoiled gradient-echo sequence for approximately 72 minutes. Before the second magnetic resonance imaging session, 2 of the groups received a rifampicin dose of 20 (n = 7) or 40 (n = 7) mg/kg, respectively. Data from regions of interest in the liver were analyzed using 2 simplifications of a 2-compartment uptake and efflux model to provide estimates for the gadoxetate uptake rate (k i ) into the hepatocytes and its efflux rate (k ef ) into the bile. Both models were assessed for goodness-of-fit in the group without rifampicin (n = 9), and the appropriate model was selected for assessing the ability to monitor DDIs in vivo. Results: Seven of 9 mice from the group without rifampicin were assessed for model implementation and reproducibility. A simple 3 parameter model (k i , k ef , and extracellular space, v ecs ) adequately described the observed liver concentration time series with mean k i = 0.47 ± 0.11 min −1 and mean k ef = 0.039 ± 0.016 min −1 . Visually, the area under the liver concentration time profile was reduced for the groups receiving rifampicin. Furthermore, tracer kinetic modeling demonstrated a significant dose-dependent decrease in the uptake (5.9-and 17.3-fold decrease for 20 mg/kg and 40 mg/kg, respectively) and efflux rates (2.2-and 7.9-fold decrease) compared with the first scan for each group.
D rug-drug interactions (DDIs) at the transporter protein level refer to the interaction between 2 or more drugs at the binding sites of membrane transporters, which may result in inhibition or enhancement of the pharmacological action of the administered compounds. 1, 2 Membrane transporters are located in various cell types and are responsible for the active transport of a wide range of endogenous and exogenous substances across the hydrophobic lipid bilayer. The liver, which plays a major role in drug metabolism and excretion, possesses a whole array of uptake and efflux transporters and is a major site of DDIs at the transporter protein level. 3, 4 It is known that interactions of drugs with membrane transporters can result in altered drug concentrations in tissues and/or blood, which in turn may have implications for both safety and efficacy. 2, 5 The influence of the organic anion transporting polypeptide (OATP) family members on pharmacokinetics has previously been reported. 6 Of particular importance in human liver are the OATP1B1, OATP1B3, and OATP2B1 transporters expressed on the sinusoidal membrane of hepatocytes, which facilitate the uptake of their drug substrate into hepatocytes and can be a determining factor in hepatic clearance. 7 After substrate uptake into hepatocytes, members of the ATP-binding cassette (ABC) superfamily of transporters expressed in the canalicular membrane, including the multidrug resistanceassociated protein 2 (ABCC2, MRP2) and the multidrug resistance protein 1 (ABCB1, MDR1, P-glycoprotein), may be involved in the efflux of drugs and their metabolites from the hepatocyte into the bile. 6, [8] [9] [10] Hepatic clearance refers to the ability of the liver to extract a drug from blood, and studies have suggested that transporter-mediated drug uptake at the sinusoidal membrane of hepatocytes can be the rate-limiting step in hepatic clearance for some drugs. [11] [12] [13] Transporter-mediated DDIs in the liver therefore have the potential to significantly alter the pharmacokinetic (PK) profile of administered drugs and, if drug levels are altered, may impact drug efficacy (if concentrations at the site of action are not adequate for effect) and/or drug safety (if concentrations are too high, leading to potential toxicity).
Extensive in vitro studies have been carried out to identify transporter-mediated DDIs.
14 However, accurately predicting the severity of clinically relevant DDIs from in vitro data is extremely challenging and ideally requires knowledge of multiple parameters, including transporter expression levels, relative affinities of transporter for coadministered drugs, mechanism of inhibition, relative extents of drug-plasma protein binding, and unbound drug concentrations. 14, 15 In addition, the clinically relevant substrates studied in vitro are not extensively studied in in vivo studies. Classically, PK information is derived from analyses of blood, urine, and feces samples; however, such analyses are often complex and time-consuming. Although in vitro data may be used to simulate plasma and liver concentration time profiles using a physiologically based PK modeling approach, 16 such an approach has limited predictive power for transporterrelated interactions. 17, 18 Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a widely used technique that can provide quantitative insights into physiological processes taking place in vivo, by monitoring the real-time distribution of a bolus of contrast agent within the body. Specific hepatobiliary contrast agents include mangafodipir trisodium (Mn-DPDP), gadobenate dimeglumine (Gd-BOPTA), and gadoxetate (Gd-EOB-DTPA). 19 Previous studies have demonstrated that gadoxetate (also known as Primovist, Eovist, and gadoxetic acid) can potentially be used to monitor hepatic transporter-mediated processes in the liver. [20] [21] [22] [23] [24] Gadoxetate has been shown to be a substrate of OATP1B1, OATP1B3, and NTCP 25 uptake transporters and of the MRP2 and MRP3 efflux transporters. 8 Various in vitro studies have demonstrated the inhibitory effect of gadoxetate on the uptake of bromosulfophthalein into OATP1B1-and OATP1B3-transfected HEK cells, 25 as well as the inhibition of gadoxetate uptake in OATP1 cRNA-injected Xenopus laevis oocytes after coadministration of bromosulfophthalein, taurocholate, rifamycin SV, and rifampicin (rifampin). 26 Inhibition of gadoxetate uptake into the liver has also been shown indirectly in preclinical experiments with rats, where rifampicin coadministration caused a reduction in the liver enhancement time series compared with controls. 27 Ulloa et al, 22, 28 using semiquantitative and quantitative analyses, demonstrated a reduction in the time constant associated with the washout in rat liver, after coadministration of estradiol-17β D-glucuronide and a dose-dependent reduction in the uptake rate and efflux kinetics (V max , K m ) after coadministration of a chemokine antagonist. More recently, Giraudeau et al 29 used a compartmental modeling approach to quantify altered gadoxetate kinetics in a rat model of advanced liver fibrosis.
In this study, we present the first preclinical application of our novel dual-input 2-compartment uptake and efflux model, first used in humans, 23 to monitor the transporter-mediated processes involved in the uptake and efflux of gadoxetate in mouse liver. Although murine OATPs differ slightly from human homologues (OATP1a/b in mice) substrate affinities are considered to be similar. Rifampicin 30 was chosen as the inhibitor for this study because it is used clinically and has previously been demonstrated to inhibit hepatic transporter-mediated uptake and efflux of gadobenate dimeglumne in rats 31 30 thereby demonstrating the efficacy of our tracer kinetic model and its ability to provide noninvasive quantitative insights into DDIs at the transporter protein level.
METHODS

Tracer Kinetic Models
Single-Input 2-Compartment Uptake and Efflux Model (2CUE Model)
The tracer kinetic model used ( Fig. 1) is based on the dual-input 2-compartment uptake and efflux model described and derived in full in Georgiou et al. 23 A dual input approach is commonly used in the analysis of human DCE liver data (ie, accounting for both arterial input function [AIF] and venous input function [VIF] ). In mouse model, the AIF and VIF signal time profiles exhibit similar temporal characteristics, 35 with negligible delay and dispersion of the VIF compared with the AIF. Because the AIF is more likely to be compromised by inflow effects, a single input C l (t) derived from the hepatic portal vein (c v (t)) was used, as defined in Equation 1:
where F p is the total plasma flow, An approximation to the 2CUE model may be obtained in the limit where the extracellular mean transit time, T e , is negligible (or similarly plasma flow → ∞). F p has a broadening effect on the input, that is, a low flow value would cause large dispersion of the input. In situations where temporal resolution is low and/or the flow is high, any dispersion of the input would be very small causing the measured flow to appear infinite. 39 In these cases, the extracellular concentration in the liver is in equilibrium with the input concentration, and hence the former can be used as the input to the intracellular compartment. Using this approximation Equation 1 reduces to:
where δ(t) is the delta function.
Animals and Experimental Procedures
DCE-MRI Protocol
All experiments were performed using a 7 T preclinical MR scanner (Bruker BioSpin MRI). The MR sequence employed for both T 1 quantification and dynamic acquisition was the modified driven equilibrium Fourier transform (MDEFT) sequence (for T 1 quantification, TR/TE = 5.94/1.42 milliseconds, flip angle = 1, 3, 7, 11, 15, and 21 degrees, field of view = 3.4 Â 3.4 cm 2 , matrix size = 128 Â 128, number of slices = 14, slice thickness = 2 mm to cover the whole liver volume). The dynamic acquisition had the same TR/TE and field of view, and a flip angle of 12 degrees. The temporal resolution of the dynamic sequence was 8.64 seconds.
Experimental Procedures
Animal experiments were performed according to the European ethical guidelines of animal experimentation, and in compliance with the UK Home Office Animals (Scientific Procedures) Act 1986, after review by the local ethics committee. All mice were scanned twice (1 week apart) after the above DCE-MRI protocol, with gadoxetate alone at session 1. Mice were scanned in 3 groups; group A received gadoxetate alone at session 2 and served as the vehicle group (n = 9, 22-weeks-old male C57, 30-35 g, Charles River, United Kingdom), and groups B and C mice also followed the DCE-MRI protocol in session 2 with coadministration of rifampicin at a dose of 20 mg/kg (n = 7, 25-weeks-old male C57, 31-35 g, The Jackson Laboratory, United Kingdom) or 40 mg/kg (n = 7, 25-weeks-old male C57, 34-40 g, Charles River, United Kingdom), respectively. Inhibition experiments (groups B and C) were used to investigate the impact of in vivo DDIs on gadoxetate pharmacokinetics in mouse liver. The antibiotic rifampicin (mainly used in the treatment of tuberculosis; clinical dose: 10 mg/kg 40 ) is a well-established inhibitor of human and rodent OATP transporters). 41 Its interaction with gadoxetate has been reported in both in vitro and in vivo studies. 26, 27 All mice were anesthetized via 3% inhaled isoflurane in a gaseous mixture (O 2 /air/N 2 O) and maintained (at 1%-2%) during the scanning process. The tail vein was cannulated using a 27-gauge (1/2-inch length) cannula secured in place using tape. The animals were transferred into the magnet's bore, and body temperature was monitored and maintained using a hot air pump. Breathing rate was also monitored.
The variable flip angle images were acquired before contrast bolus administration for T 1 measurement, followed by the dynamic sequence. Approximately 2 minutes after the start of the dynamic acquisition, a bolus of gadoxetate at a dose of 25 μmol/kg was injected into the lateral tail vein. The total scanning time was approximately 72 minutes, and the total anaesthesia time did not exceed 90 minutes. At the end of session 1, mice were recovered from the anesthesia using oxygen and a heated recovery box and kept for a week before next session.
For group A session 2, mice were scanned after the same procedures as session 1. For groups B and C session 2, mice followed the same animal handling and imaging procedures described for session 1, but 30 minutes before administration of gadoxetate, animals were intravenously injected with the appropriate rifampicin dose using an automated injector. At the end of the experiment, all mice were terminated by overdose of anesthesia (under procedure 2 of PPL40/3268), confirmed by schedule 1 method.
Postprocessing
Data were processed in Matlab (R2014a, MathWorks, Natick, MA) and ImageJ. No motion correction was performed. Regions of interest (ROIs) were defined to cover the tissues of interest (liver and hepatic portal vein) and used to generate the corresponding T 1 estimates by fitting the variable flip angle data. The same ROIs were also applied to extract signal intensity time series from the dynamic images. These were converted to concentration series using the baseline T 1 estimates and assuming a R 1 relaxivity of gadoxetate of 4.8 mM 42 This process of converting MR signal into concentration has been described in detail previously. 20 
Model and Reproducibility Study
The 2 variations of the 2CUE model were fitted to the dynamic data (using the least squares fitting algorithm from Matlab's optimization toolbox) obtained from group A and the Akaike information criterion (AIC) was used to determine the most appropriate model for the data. The goodness-of-fit and optimization performance was assessed using Akaike probabilities 43 (P a ) and by examining whether the generated parameters are independent of the initial input and within the applied constraints (F p < 10 mL/min/mL, v ecs < 0.5 mL/mL, k i < 10 min ). For the Akaike probabilities, the number of dynamic points and the number of free parameters were used, which was either 4 or 3 for the full and simplified version of the 2CUE tracer kinetic model, respectively. A threshold of P a < 0.5 for the Akaike probability was defined in favor of the simpler model to best describe the data. After this initial implementation of both models, data fitted with the most appropriate model were used to assess the reproducibility of the parameter estimates, by calculating the differences between the parameters in each session. These were used to calculate the reproducibility of the parameter estimates at the group (95% confidence intervals) and individual level (repeatability). 44, 45 Inhibitor Studies
Based on the results of the initial implementation of the models, the appropriate model was used to fit the liver concentration time series of vehicle (group A) and both inhibitor groups (groups B and C) for both sessions. Changes in the parameter estimates within each group after the second session of the DCE-MRI experiment were assessed with a paired t test.
RESULTS
Model and Reproducibility Study
The final study cohort included 8 mice in each session for group A. Two mice were excluded from the analysis (1 from each session) as a result of unsuccessful contrast administration. All successful scans were used for model comparison. Baseline T 1 relaxation times in the liver and VIF for group A are shown in Table 1 . Respiratory motion artifacts prevented the characterization of the VIF signal in 6 of the 16 scans. For this reason, a population average input function was derived from those scans where it was possible to extract a VIF (n = 10) and used as the input to the tracer kinetic model for all mice. Liver concentration time series were fitted using the proposed models (2CUE: Table 2 summarizes the results of both tracer kinetic models. F p and v ecs estimates using the 2CUE model showed large variations, and the results were dependent on the initial estimates used in the optimization. Furthermore, in half of the cases, v ecs estimates reached the upper boundary limit. In the absence of the imposed constraints (v ecs <0.5 mL/mL), v ecs estimates were converging toward nonphysiological values (>1 mL/mL). On the other hand, the simplified form of the model (2CUE Te→0 ) generated more robust v ecs estimates, with less variation and well within the constraints applied.
Example of model fits using both models are illustrated in Figure 2 . By visual inspection both models provide good fits to the data. Figure 2A demonstrates an example of a 2CUE model fit that generated an estimate of v ecs well within the constraints. However, the estimated Akaike probability suggests that the extra complexity of 2CUE is not justified over the use of the simplified form with negligible T e (P a < 0.5) (Fig. 2B) . Figure 2C illustrates an example of the 2CUE model v ecs estimate reaching the upper boundary limit with an Akaike probability larger than 0.5. In fact, for half of the data, the full form of the 2CUE model generated Akaike probabilities larger than 0.5; however, in all these cases, v ecs reached the upper boundary limit. Based on the fact that 2CUE Te→0 generated parameter estimates independent of the initial input and the fact that Akaike probabilities were favoring the full form of 2CUE model only in cases where v ecs estimates reached the upper limit (Fig. 2, C and D) , the 2CUE Te→0 was selected as the most suitable tracer kinetic model given the limitations of the acquisition technique used (eg, low temporal resolution, noise levels).
A total of 7 group A mice successfully scanned on both sessions were used in the reproducibility assessment, which is summarized in Table 3 . All parameter differences were tested for normality (ShapiroWilk test, P > 0.05) and for dependence of absolute value of the difference against the mean value of the 2 sessions (Kendall τ, P > 0.05). The most reproducible parameter was the uptake rate (k i ) in the hepatocytes, and the least reproducible parameter was the efflux rate (k ef ) from the hepatocytes (within-subject coefficient of variation = 0.23, 0.14, 0.29 for v ecs , k i , and k ef , respectively). Repeatability and 95% confidence interval for the mean difference illustrate the magnitude of deviation for individual estimates or a group average that would allow assessment of a significant change after repetitive measurements, at the individual or group level, respectively.
Inhibitor Studies
For the 20 mg/kg rifampicin group (group B), all 7 mice were successfully scanned in both sessions. For the 40 mg/kg rifampicin group (group C), all 7 mice were successfully scanned in session 1 but 2 had to be excluded from session 2 due to unsuccessful injections, which resulted in delivery of less than the full dose of rifampicin. For group B, VIFs were successfully obtained in 4/7 mice for session 1 and all 7 mice for session 2. For group C, VIFs were successfully obtained in 6/7 mice for session 1 and all 5 mice for session 2. These VIFs were averaged to produce population VIFs for each group and each session. The variable flip angle data were used for baseline T 1 estimation of liver tissue and VIF. No significant differences were found in the T 1 estimates between session 1 and session 2 at the 95% significance level ( Table 1) .
The effect of rifampicin coadministration on gadoxetateenhanced liver and portal concentration time series is shown in Figure 3 . The inhibitor caused a decline in the wash-in rate, a reduction in the peak concentration reached, and a drop in the washout rate compared with the controls. There is a statistically significant increase (one-way analysis of variance P < 0.0001) in the average portal concentration (measured between 60 and 70 minutes postcontrast agent administration) for increasing rifampicin concentration. The reduced uptake of gadoxetate into the liver is the likely cause of these increased portal levels of gadoxetate.
Examples of fitted data for vehicle (group A) and inhibitor groups (B and C) for both sessions are illustrated in Figure 4 . Summary statistics are shown in Table 1 , and the fold change in the mean estimates for all parameters are illustrated in Figure 5 . The results demonstrate there is a significant reduction in both the gadoxetate uptake and efflux rates in hepatocytes of mice treated with 20 mg/kg or 40 mg/kg rifampicin, compared with vehicle treated controls (paired t test, P < 0.01). Furthermore, there were significant differences in k i and k ef parameter estimates between session 2 of the 20 mg/kg and 40 mg/kg rifampicin groups, which suggests a dose-dependent reduction in the uptake (2 sampled t test, P = 0.0015) and efflux rates (2 sampled t test, P = 0.0068) due to rifampicin coadministration. Significant differences were also found between session 1 parameter estimates of group A versus group B and group A versus group C (2 sampled t test, P < 0.05), but not between groups B and C.
DISCUSSION
Model and Reproducibility Study
Two approximations to the dual-input 2-compartment uptake and efflux model 23 were implemented to describe the pharmacokinetics of gadoxetate in mouse liver. In the first, and in contrast to humans, a single input derived from the VIF was used since, at the temporal resolution of the DCE experiment in the present study, the AIF and VIF exhibited similar temporal characteristics, that is, negligible dispersion or delay compared with the AIF. 35 The VIF was chosen as the input because the T 1 estimates and signal intensity time series in the AIF suggested that arterial blood was susceptible to inflow effects. The supply to the liver via the hepatic portal vein accounts for approximately 75% of the total blood. In the second, the additional approximation of negligible extracellular mean transit time was made.
Although both models were able to describe the liver time-series data, the full form of the single input 2CUE model did not always obtain v ecs estimates within the imposed physiological range and was not robust to the starting parameters. F p parameter also showed large variation within the group, indicating the inability of the model to accurately quantify both of these parameters in a mouse model, given the temporal resolution of the dynamic scan. Based on the mean F p , v ecs , and k i estimates, the extracellular mean transit time (T e ) is estimated to be less than 8 seconds. Given that this is lower than the temporal resolution used, it is unsurprising that attempting to fit this model results in large variations in F p and v ecs estimates. In contrast, the 2CUE Te→0 model assumes a negligible extracellular mean transit time and is able to obtain more robust v ecs parameter estimates.
The reproducibility assessment was based on the 2CUE Te→0 model, which best describes the data acquired. The results obtained provide a description of the transport of gadoxetate into and out of the mouse hepatocytes. The uptake rate reflects the transport of gadoxetate via specific transporters, such as OATPs and NTCP, expressed on the sinusoidal membrane of hepatocytes. 8, 25 Efflux rates describe the active transport of gadoxetate out of hepatocytes across the canalicular membrane and into the bile ducts by efflux transporters, including MRP2. 8, 29 It is assumed here that any efflux back into the blood via sinusoidal transporters such as MRP3 and MRP4 is negligible. The substrate specificity of other canalicular efflux transporter candidates (eg, BCRP, P-gp) toward gadoxetate is yet to be investigated. 8, 22 The uptake and efflux parameters therefore provide a measure of the transport of gadoxetate by a combination of transporters.
Although the uptake rate exhibits low variability, the efflux rate k ef showed lower reproducibility. This could be due to several factors, for example, individual variability in intracellular binding of gadexotate or differing levels of competing endogenous substrates/inhibitors within the hepatocytes. Despite this observed variability in the efflux rates at the individual level, the results clearly demonstrate the sensitivity of DCE-MRI techniques to monitor changes in transporter-mediated processes. The 95% confidence intervals suggest that a group change of 16% and 30% in the mean uptake and efflux rate, respectively, would be significant. Changes of this magnitude could potentially occur with certain transporter genetic variants with reduced activity, 46, 47 suggesting that DCE-MRI techniques could prove useful in determining the impact of pharmacogenomic variability on in vivo DDIs in the liver.
Inhibitor Studies
The experiments described involved a series of control scans in session 1, which serve as a baseline for the functional activity of the liver for each mouse. In session 2, rifampicin, a well-established inhibitor of both OATP and MRP2, 48, 49 was administered in groups B (20 mg/kg dose) and C (40 mg/kg dose) before DCE-MRI analyses to examine whether DDIs at the transporter protein level can be monitored Repeatability is the value of the 95% limit for the difference between 2 measurements on an individual.
CI indicates confidence interval for the control group. using the proposed DCE-MRI techniques. It is important to note that the clinically prescribed dose is 10 mg/kg, but a study suggested that the effect of a therapeutic dose of rifampicin in gadoxetate livertime series would be very small 26 due to the high binding affinity of the drug to plasma proteins, that is, approximately 80% bound, resulting in 20% free drug available to interact with hepatic transporters. 50, 51 For this reason, we have used higher doses of rifampicin to study the principle of a rifampicin/gadoxetate DDI. It is, however, worth noting that the extent of plasma protein binding of therapeutic drugs varies across a wide range of values, with, for example, some drugs demonstrating low binding and higher levels of free drug. The binding affinity may also differ between humans and rodents.
Visual assessment of liver concentration-time profiles reveals large changes between session 1 and session 2 of inhibitor groups. Rifampicin was administered 30 minutes before gadoxetate bolus administration, as suggested in Kato et al. 27 This was to allow for the drug to bind to the transporter proteins and produce an inhibitory effect, but also to allow the experimental procedures to be undertaken in a consistent and reproducible manner. However, inhibition alone may require less time, as described in Daali et al. 31 Drug-drug interaction at the sinusoidal site inhibited the transport of gadoxetate into the hepatocytes, which caused an increase in plasma gadoxetate level. The wash-in and washout phases in the liver concentration time series were visibly compromised at both doses, compared with their control groups.
Using the DCE technique allows the derivation of quantitative information about the degree of reduction in the rate of active transport of gadoxetate. The gadoxetate uptake rates were significantly compromised, with 5.9-and 17.3-fold decreases in the mean uptake rate (P < 0.01) after 20 mg/kg and 40 mg/kg rifampicin, respectively, compared with the corresponding control mean uptake rates. The mean efflux rates exhibited 2.2-and 7.9-fold decreases (P < 0.01), respectively, compared with the control scans. Moreover, the reduction in both uptake and efflux rates was dose-dependent (P < 0.05). The very large changes observed in this study give some confidence that a similar technique would be sensitive to inhibition of uptake at a more clinically relevant dose. FIGURE 5. Box plots showing the fold-change in the parameter estimates between session 1 and 2 of each group (*significant change following paired t test P < 0.01; **significant change after a 2-sample t test P < 0.05).
Limitations of this study include age differences, the use of different suppliers, and the fact that the mice were not controlled for fasting before the studies. These factors may cause experimental variations due to intrinsic physiological differences between mice. Despite these variations, the study was designed such that each individual mouse had a control scan (ie, session 1, no rifampicin) and statistical tests for the effect of rifampicin were performed for the same mice under different conditions rather than between groups of mice. There were no differences in parameter estimates for the control scans (session 1) between the groups B and C (see Table 1 ). Therefore, the detected dose-dependent change is likely to be due to the effect of rifampicin, rather than any physiological differences between the groups.
Motion-induced artifacts precluded the use of individual VIF, and this is of particular importance when an inhibitor is coadministered because the potency of inhibition might differ between mice, and hence an individually acquired VIF would partly account for this. Furthermore, noise in the acquired time series might have reduced the sensitivity of the experiment. In addition, contrast-to-noise ratio is lower in the experiments with the inhibitor because of the reduced enhancement. Triggering was avoided because it would further compromise the temporal resolution of the dynamic series and postprocessing image registration was not performed due to technical limitations. We also acknowledge the fact that transporter-mediated processes might be governed by nonlinear kinetics, for example, Michaelis Menten kinetics, and the rate of uptake or efflux might saturate at high concentrations of gadoxetate either in the sinusoidal site of the hepatocytes or within the hepatocyte cells. As described previously, due to the maximum limit in the number of identifiable parameters in a 2-compartment tracer kinetic model, 52 the absence of an explicit solution to models that incorporate nonlinear kinetics and the limitations imposed by acquisition requirements, linear approximations for both uptake and efflux processes were assumed.
23,53
Implications
The results of this study highlight the potential of hepatobiliary contrast agents such as gadoxetate to be used as a tool to investigate DDIs in the liver, in vivo. Dynamic contrast-enhanced MRI with gadoxetate offers the opportunity to monitor the disposition of the tracer in vivo without the need for regular sampling of blood, urine, and feces and provides direct, real-time information from tissues of interest (eg, liver, kidneys) that can be used to improve and refine pharmacokinetic models. This becomes particularly helpful when modeling hepatobiliary transport because it provides easy access to additional information, such as biliary excretions. Studying interactions at the level of OATP transporters with clinically relevant drugs can be difficult, particularly if a drug is a potent OATP inhibitor, and may lead to drug-induced toxicity for compounds that are substrates of OATPs. However, preclinical mouse models can certainly supplement such studies, although the murine homologues OATP1a/1b do differ slightly from human OATP1B1/ 1B3/2B1, they share both sequence similarities (eg, OATP1B1 and OATP1b2 have 65% amino acid identity 54 ) and substrates and demonstrate similar hepatic uptake PK. 55 The use of humanized OATP mouse models also shows promise. 2, 56 Thus DCE-MRI with gadoxetate offers the opportunity to monitor the disposition of the tracer in vivo and provides direct information from tissues of interest (eg, liver, kidneys) that can be used to improve and refine PK models.
Gadoxetate is routinely used in liver imaging in clinical practice and is considered safe for patients without renal impairment. 57, 58 However, in March 2017 the European Medicines Agency recommended the suspension of the marketing authorizations for 4 linear gadoliniumbased contrast agents due to evidence that small amounts of gadolinium may be deposited in the brain. 59 Gadoxetate is also a linear agent, and while it was not one of the agents recommended for suspension due to its important diagnostic utility, the extent to which this may affect its use in clinical DDI studies is uncertain. Given its current diagnostic utility for the assessment of liver function and parenchymal liver disease, the significance of pharmacologic OATP blockade, which may alter clinical measurements of hepatic gadoxetate uptake, may be an important bias that radiologists and clinicians should consider.
CONCLUSIONS
In conclusion, this study reports a novel tracer kinetic model that assesses liver function in terms of both the uptake and efflux of gadoxetate alone or in the presence of a transporter inhibitor. The model was implemented in mouse models, where the reproducibility of the technique was studied and subsequently tested for its ability to detect and quantify in vivo DDIs at the transporter-protein level, using the clinically relevant OATP inhibitor rifampicin. Where there is uncertainty in the level of inhibition expected from the coadministration of drugs in humans, this technique may potentially provide an alternative and safer tool to investigate DDIs in vivo.
